NCT07906080
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07906080
Title A Multicenter, Phase I Study to Evaluate the Feasibility and Safety of Autologous Cytokine-Induced Killer Cells (CIK_D332) in Combination With Tafasitamab and Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (FOCUS)
Acronym FOCUS
Recruitment Not yet recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Istituto Oncologico Veneto IRCCS
Indications
Therapies
Age Groups: senior | adult
Covered Countries ITA


No variant requirements are available.